Overview

A Study to Evaluate the Safety and Pharmacokinetics ABBV-399 in Japanese Participants With Solid Tumors

Status:
Completed
Trial end date:
2019-03-04
Target enrollment:
Participant gender:
Summary
An open-label, dose-escalation study designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ABBV-399 in participants with advanced solid tumors.
Phase:
Phase 1
Details
Lead Sponsor:
AbbVie